The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and ...

For individuals with type 1 diabetes, low-glucose alerts improve the time below range for drivers and reduce the incidence of ...

Without prompt treatment, severe hypoglycemia can lead to brain or organ damage or even death. If a person frequently experiences episodes of hypoglycemia, it can have a negative long-term effect ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

Mr. Harris is an experienced board member and commercial leader with a proven track record in the industry. Mr. Harris has spearheaded global product launches, built and led high-performing commercial ...

When this occurs, it is known as drug-induced hypoglycemia. The American Diabetes Association treatment guidelines highlight that insulin and sulfonylureas as the drugs with the highest risk of ...